Answers are grounded in this paper and cite their sources.
Malignant tumors are frequently accompanied by neurological damage or neuroinflammation, severely compromising patient outcomes. Consequently, the development of multitarget small molecules possessing concurrent anticancer and neuroprotective properties is of paramount importance. Capitalizing on the pharmacological relevance of the 2H-1,4-benzoxazin-3(4H)-one scaffold and the structural versatility of 1,2,3-triazoles, fifteen novel benzoxazinone–triazole hybrids were designed and synthesized via terminal alkyne functionalization and subsequent click chemistry. Their antitumor efficacy against lymphoma cell lines and their neuroprotective effects were systematically evaluated. Most hybrids exhibited pronounced antiproliferative activity against Ramos and REC-1 cells, with compound 11n emerging as the most potent derivative, displaying an IC50 value of 3.03 μM against Ramos cells. Furthermore, compound 11n afforded robust protection against glutamate-induced injury in HT22 cells, significantly restoring cell viability to 48.74% at 10 μM, thereby outperforming the reference drug resveratrol. Collectively, these findings demonstrate that compound 11n features a compelling dual-action profile, representing a promising multitarget lead compound for further therapeutic optimization.
No takes yet. Share an insight, caveat, or question.
Xiao-yi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: